Novo Nordisk responded this week to the Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to prevent competition and raise prices. Moderna stock surged on Thursday after its first-quarter earnings report blew past Wall Street’s expectations. And Johnson & Johnson announced its plans to pay nearly…
Originally published on Quartz : Original article